Atara Biotherapeutics, Inc. (ATRA)
6.69
+0.19
(+2.92%)
USD |
NASDAQ |
Nov 18, 16:00
6.69
0.00 (0.00%)
After-Hours: 20:00
Atara Biotherapeutics Net Income (Quarterly) : -2.229M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -2.229M |
| June 30, 2026 | -4.834M |
| March 31, 2026 | -4.145M |
| December 31, 2025 | -3.406M |
| September 30, 2025 | -4.303M |
| June 30, 2025 | 2.387M |
| March 31, 2025 | 38.01M |
| December 31, 2024 | -12.69M |
| September 30, 2024 | -21.91M |
| June 30, 2024 | -19.05M |
| March 31, 2024 | -31.75M |
| December 31, 2023 | -60.45M |
| September 30, 2023 | -69.80M |
| June 30, 2023 | -71.11M |
| March 31, 2023 | -74.77M |
| December 31, 2022 | -74.57M |
| September 30, 2022 | -84.09M |
| June 30, 2022 | 18.47M |
| March 31, 2022 | -88.10M |
| December 31, 2021 | -93.35M |
| September 30, 2021 | -84.66M |
| June 30, 2021 | -83.79M |
| March 31, 2021 | -78.34M |
| December 31, 2020 | -81.31M |
| September 30, 2020 | -74.35M |
| Date | Value |
|---|---|
| June 30, 2020 | -77.46M |
| March 31, 2020 | -73.51M |
| December 31, 2019 | -78.50M |
| September 30, 2019 | -71.90M |
| June 30, 2019 | -74.33M |
| March 31, 2019 | -66.26M |
| December 31, 2018 | -80.01M |
| September 30, 2018 | -58.36M |
| June 30, 2018 | -50.88M |
| March 31, 2018 | -41.44M |
| December 31, 2017 | -35.31M |
| September 30, 2017 | -31.10M |
| June 30, 2017 | -27.43M |
| March 31, 2017 | -25.65M |
| December 31, 2016 | -18.24M |
| September 30, 2016 | -25.37M |
| June 30, 2016 | -18.88M |
| March 31, 2016 | -16.56M |
| December 31, 2015 | -21.25M |
| September 30, 2015 | -11.87M |
| June 30, 2015 | -14.94M |
| March 31, 2015 | -9.16M |
| December 31, 2014 | -10.53M |
| September 30, 2014 | -5.919M |
| June 30, 2014 | -4.511M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | -0.311M |
| Savara, Inc. | -42.99M |
| Arrowhead Pharmaceuticals, Inc. | -428.88M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.224M |
| Total Expenses (Quarterly) | 3.453M |
| EPS Diluted (Quarterly) | -0.1454 |
| Enterprise Value | 106.54M |
| Gross Profit Margin (Quarterly) | 78.35% |
| Profit Margin (Quarterly) | -182.1% |
| Earnings Yield | -18.33% |
| Normalized Earnings Yield | -16.02 |